TG Therapeutics Net Income Applicable To Common Shares Over Time
| TGTX Stock | USD 34.80 0.20 0.57% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out TG Therapeutics Performance and TG Therapeutics Correlation. TGTX |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of TG Therapeutics. If investors know TGTX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about TG Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.97) | Earnings Share (0.10) | Revenue Per Share 1.829 | Quarterly Revenue Growth (0.49) | Return On Assets (0.0007) |
The market value of TG Therapeutics is measured differently than its book value, which is the value of TGTX that is recorded on the company's balance sheet. Investors also form their own opinion of TG Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is TG Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because TG Therapeutics' market value can be influenced by many factors that don't directly affect TG Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between TG Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if TG Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, TG Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Applicable To Common Shares Analysis
Compare TG Therapeutics and related stocks such as Madrigal Pharmaceuticals, Intercept Pharmaceuticals, and Terns Pharmaceuticals Net Income Applicable To Common Shares Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDGL | (47.4 M) | (47.4 M) | (62.8 M) | (90.2 M) | (86.2 M) | (68.7 M) | (26.4 M) | (31.2 M) | (32.8 M) | (83.9 M) | (202.2 M) | (241.8 M) | (295.4 M) | (265.8 M) | (252.5 M) |
| TERN | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (68.6 M) | (29.4 M) | (50.2 M) | (60.3 M) | (54.3 M) | (57 M) |
| HEPA | (22.2 M) | (22.2 M) | (22.2 M) | (22.2 M) | (22.2 M) | (17 M) | (14.9 M) | (13.1 M) | (17.9 M) | (12.2 M) | (20.4 M) | (32.7 M) | (45.3 M) | (40.8 M) | (38.8 M) |
| EXEL | 75.7 M | 75.7 M | (147.6 M) | (244.8 M) | (268.5 M) | (169.7 M) | (70.2 M) | 154.2 M | 690.1 M | 321 M | 111.8 M | 231.1 M | 182.3 M | 209.6 M | 220.1 M |
| VKTX | (21.9 M) | (21.9 M) | (21.9 M) | (21.9 M) | (21.9 M) | (23.4 M) | (14.7 M) | (20.6 M) | (22.1 M) | (25.8 M) | (39.5 M) | (55 M) | (68.9 M) | (62 M) | (58.9 M) |
| BTAI | (636 K) | (636 K) | (636 K) | (636 K) | (636 K) | (636 K) | (2.1 M) | (4.5 M) | (19.3 M) | (33 M) | (82.2 M) | (106.9 M) | (165.8 M) | (149.2 M) | (141.7 M) |
| AKRO | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (82.2 M) | (43.8 M) | (79.2 M) | (100.8 M) | (112 M) | (100.8 M) | (105.9 M) |
| XFOR | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (20.9 M) | (25 M) | (36.3 M) | (53.4 M) | (62.1 M) | (102.6 M) | (96.4 M) | (86.8 M) | (82.4 M) |
| PDSB | (32.4 M) | (32.4 M) | (32.4 M) | (32.4 M) | (32.4 M) | (32.4 M) | (4.5 M) | (3.4 M) | (3.8 M) | (7 M) | (14.8 M) | (16.9 M) | (40.9 M) | (36.8 M) | (34.9 M) |
TG Therapeutics and related stocks such as Madrigal Pharmaceuticals, Intercept Pharmaceuticals, and Terns Pharmaceuticals Net Income Applicable To Common Shares description
The net income that remains after preferred dividends have been deducted, available to common shareholders.My Equities
My Current Equities and Potential Positions
| TG Therapeutics | TGTX |
| Classification | Cancer Fighters |
| Location | New York; U.S.A |
| Exchange | NASDAQ Exchange |
USD 34.8
Additional Tools for TGTX Stock Analysis
When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.